Market Overview

Hemispherx Biopharma Says FDA Panel Voted 9-4 Against Ampligen Effocacy

Related HEB
Hemisphrex Announces Publication of Ampligen Safety Profile Across Diverse Animal Species
Hemispherx Shares Jump 13+% Following Release of Summarized Phase 1/2 Data on Flu Combo

Hemispherx Biopharma, Inc. (NYSE MKT:HEB) (the "Company" or "Hemispherx") today announced the outcome of the meeting of the Arthritis Advisory Committee (the "AAC") of the U.S. Food and Drug Administration (the "FDA") on the New Drug Application ("NDA") for Ampligen^® for Chronic Fatigue Syndrome ("CFS").

On the question: "Considering the totality of the data, is there substantial evidence of efficacy for Ampligen for the treatment of patients with chronic fatigue syndrome (CFS)?," the AAC voted 9 no, 4 yes and 1 AAC member left the room and did not vote.

Posted-In: News FDA

 

Most Popular

Related Articles (HEB)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free